JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 9, 2007; DOI: 10.1124/jpet.106.115840


0022-3565/07/3212-642-647$20.00
JPET 321:642-647, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.115840v1
321/2/642    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takasu, T.
Right arrow Articles by Yamaguchi, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takasu, T.
Right arrow Articles by Yamaguchi, O.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETANILIDE
*CARBACHOL CHLORIDE

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Effect of (R)-2-(2-Aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective beta3-Adrenoceptor Agonist, on Bladder Function

Toshiyuki Takasu, Masashi Ukai, Shuichi Sato, Tetsuo Matsui, Itsuro Nagase, Tatsuya Maruyama, Masao Sasamata, Keiji Miyata, Hisashi Uchida, and Osamu Yamaguchi

Institute for Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (T.T., M.U., S.S., Te.M., I.N., Ta.M., M.S., K.M.); and Department of Urology, Fukushima Medical University, Fukushima, Japan (H.U., O.M.)

We evaluated the pharmacological characteristics of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]-ethyl} acetanilide (YM178). YM178 increased cyclic AMP accumulation in Chinese hamster ovary (CHO) cells expressing human beta3-adrenoceptor (AR). The half-maximal effective concentration (EC50) value was 22.4 nM. EC50 values of YM178 for human beta1- and beta2-ARs were 10,000 nM or more, respectively. The ratio of intrinsic activities of YM178 versus maximal response induced by isoproterenol (nonselective beta-AR agonist) was 0.8 for human beta3-ARs, 0.1 for human beta1-ARs, and 0.1 for human beta2-ARs. The relaxant effects of YM178 were evaluated in rats and humans bladder strips precontracted with carbachol (CCh) and compared with those of isoproterenol and 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one hydrochloride (CGP-12177A) (beta3-AR agonist). EC50 values of YM178 and isoproterenol in rat bladder strips precontracted with 10–6 M CCh were 5.1 and 1.4 µM, respectively, whereas those in human bladder strips precontracted with 10–7 M CCh were 0.78 and 0.28 µM, respectively. In in vivo study, YM178 at a dose of 3 mg/kg i.v. decreased the frequency of rhythmic bladder contraction induced by intravesical filling with saline without suppressing its amplitude in anesthetized rats. These findings suggest the suitability of YM178 as a therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence.


Received October 18, 2006; accepted February 8, 2007.

Address correspondence to: Dr. Toshiyuki Takasu, Pharmacology Research Laboratories, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 Japan. E-mail: toshiyuki.takasu{at}jp.astellas.com




This article has been cited by other articles:


Home page
Therapeutic Advances in UrologyHome page
K.-E. Andersson
Prospective pharmacologic therapies for the overactive bladder
Therapeutic Advances in Urology, June 1, 2009; 1(2): 71 - 83.
[Abstract] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. S. R. Lashinger, M. S. Steiginga, J. P. Hieble, L. A. Leon, S. D. Gardner, R. Nagilla, E. A. Davenport, B. E. Hoffman, N. J. Laping, and X. Su
AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome
Am J Physiol Renal Physiol, September 1, 2008; 295(3): F803 - F810.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Hicks, G. P. McCafferty, E. Riedel, N. Aiyar, M. Pullen, C. Evans, T. D. Luce, R. W. Coatney, G. C. Rivera, T. D. Westfall, et al.
GW427353 (Solabegron), a Novel, Selective beta3-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 202 - 209.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.